Matter Bio, a NYC-based biotech company dedicated to preserving genome integrity and extending healthy human lifespan, raised $7M in Seed funding.
The round was led by Lifespan Vision Ventures, with participation from quadraScope Ventures and others, and includes grant support from NIH, NCI, and NIEHS.
The company intends to use the funds to conduct further research into the information theory of aging at a genomic level, file an IND, and start a Phase 1/2a clinical trial in solid cancer.
Matter Bio operates at the forefront of longevity biotechnology, leveraging science and innovative approaches to address the complexities of aging. It tackles the problem of genome instability holistically, addressing the issue through a multi-pronged approach:
- Reading Mutation: Detecting and identifying loss of genomic information.
- Reversing: Correcting integrated mutations and reintroducing original genetic information.
- Removing: Eliminating cells that are too damaged to be repaired, such as cancerous, clonal, and senescent cells.
The company has assembled a team of scientists and executives, including co-founders such as George Church, PhD, a pioneer in genome sequencing and gene editing, Jan Vijg, PhD, an expert in genome instability and somatic mutations, and Claudia Gravekamp, PhD, an expert in attenuated bacterial therapeutics.